COH34 analog 1

CAS No. 314248-24-3

COH34 analog 1( —— )

Catalog No. M32852 CAS No. 314248-24-3

COH34 analog 1 is a COH34 oxidation analogue that can be used to synthesize active compounds.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 65 Get Quote
10MG 104 Get Quote
25MG 210 Get Quote
50MG 342 Get Quote
100MG 537 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    COH34 analog 1
  • Note
    Research use only, not for human use.
  • Brief Description
    COH34 analog 1 is a COH34 oxidation analogue that can be used to synthesize active compounds.
  • Description
    COH34 analog 1, a metabolite, is an oxidized analog of COH34. COH34 is a potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    314248-24-3
  • Formula Weight
    325.38
  • Molecular Formula
    C18H15NO3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (307.33 mM; Ultrasonic )
  • SMILES
    Cc1ccc(cc1)S(=O)(=O)\N=C\c1c(O)ccc2ccccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chen SH, et al. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies. Sci Adv. 2019 Apr 10;5(4):eaav4340.?
molnova catalog
related products
  • Compound C108

    Compound C108 is an inhibitor of GTPase-activating protein SH3 domain-binding protein 2 (G3BP2). Compound C108 can be used in studies about breast tumors and esophageal squamous cell carcinoma.

  • MAGE-A3 195-203

    This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in treating patients with MAGE-3-positive malignant tumors.

  • Methylophiopogonanon...

    Methylophiopogonanone A has anti-inflammatory and anti-oxidative properties.